Startseite>>Signaling Pathways>> GPCR/G protein>> mGluR >>L-AP4

L-AP4 (Synonyms: L(+)2amino4phosphorobutanoic acid, LAPB)

Katalog-Nr.GC17932

L-AP4 (L-APB) ist ein potenter und spezifischer Agonist fÜr die mGluRs der Gruppe III mit EC50s von 0,13, 0,29, 1,0, 249 μM fÜr mGlu4-, mGlu8-, mGlu6- bzw. mGlu7-Rezeptoren.

Products are for research use only. Not for human use. We do not sell to patients.

L-AP4 Chemische Struktur

Cas No.: 23052-81-5

Größe Preis Lagerbestand Menge
1mg
70,00 $
Auf Lager
5mg
138,00 $
Auf Lager
10mg
241,00 $
Auf Lager
50mg
1.028,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

L-APB is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively.

Paw withdrawal threshold in response to application of von Frey filaments before spinal nerve ligation is 22.6±2.4 g. The mechanical threshold decreases significantly (2.3±0.5 g, P

References:
[1]. Selvam C, et al. Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites. J Med Chem. 2018 Mar 8;61(5):1969-1989.
[2]. Chen SR, et al. Distinct roles of group III metabotropic glutamate receptors in control of nociception and dorsal horn neurons in normal and nerve-injured Rats. J Pharmacol Exp Ther. 2005 Jan;312(1):120-6.

Bewertungen

Review for L-AP4

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for L-AP4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.